PL3177644T3 - Immunologiczne reagenty wiążące do PD-1 - Google Patents
Immunologiczne reagenty wiążące do PD-1Info
- Publication number
- PL3177644T3 PL3177644T3 PL15750136T PL15750136T PL3177644T3 PL 3177644 T3 PL3177644 T3 PL 3177644T3 PL 15750136 T PL15750136 T PL 15750136T PL 15750136 T PL15750136 T PL 15750136T PL 3177644 T3 PL3177644 T3 PL 3177644T3
- Authority
- PL
- Poland
- Prior art keywords
- immunological reagents
- reagents binding
- binding
- immunological
- reagents
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033177P | 2014-08-05 | 2014-08-05 | |
| US201462053366P | 2014-09-22 | 2014-09-22 | |
| US201462093368P | 2014-12-17 | 2014-12-17 | |
| PCT/IB2015/055943 WO2016020856A2 (en) | 2014-08-05 | 2015-08-05 | Immunological reagents |
| EP15750136.2A EP3177644B1 (en) | 2014-08-05 | 2015-08-05 | Immunological reagents binding to pd-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3177644T3 true PL3177644T3 (pl) | 2021-06-14 |
Family
ID=53836144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15750136T PL3177644T3 (pl) | 2014-08-05 | 2015-08-05 | Immunologiczne reagenty wiążące do PD-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9982053B2 (pl) |
| EP (1) | EP3177644B1 (pl) |
| JP (1) | JP6629321B2 (pl) |
| KR (1) | KR102357893B1 (pl) |
| CN (1) | CN107074947B (pl) |
| AU (1) | AU2015298356B2 (pl) |
| CA (1) | CA2957258C (pl) |
| DK (1) | DK3177644T3 (pl) |
| ES (1) | ES2847311T3 (pl) |
| PL (1) | PL3177644T3 (pl) |
| PT (1) | PT3177644T (pl) |
| SG (1) | SG11201700672YA (pl) |
| WO (1) | WO2016020856A2 (pl) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| PL3177644T3 (pl) * | 2014-08-05 | 2021-06-14 | MabQuest SA | Immunologiczne reagenty wiążące do PD-1 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
| US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| SI3328419T1 (sl) | 2015-07-30 | 2021-11-30 | Macrogenics, Inc. | PD-1-vezavne molekule in postopki uporabe le-teh |
| EP3355920A4 (en) | 2015-09-29 | 2019-05-15 | Celgene Corporation | PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF |
| BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
| AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| WO2017125815A2 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
| CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
| KR20230091191A (ko) | 2016-05-27 | 2023-06-22 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| WO2017218707A2 (en) * | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| AU2017329024A1 (en) | 2016-09-19 | 2019-03-21 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
| US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
| BR112019007369A2 (pt) | 2016-10-11 | 2019-07-16 | Agenus Inc | anticorpos anti-lag-3 e métodos de uso dos mesmos |
| MA49863A (fr) | 2016-11-01 | 2020-06-17 | Anaptysbio Inc | Anticorps dirigés contre la mort programmée 1 (pd -1) |
| CN110392694B (zh) * | 2016-11-02 | 2023-08-04 | 震动疗法股份有限公司 | 针对pd-1的抗体及其用途 |
| CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
| MA50949B1 (fr) | 2016-12-07 | 2023-12-29 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| US11814429B2 (en) * | 2017-01-06 | 2023-11-14 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (PD-1) |
| PL3565844T3 (pl) | 2017-01-09 | 2023-06-12 | Tesaro Inc. | Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1 |
| AU2018207172B2 (en) | 2017-01-13 | 2023-10-12 | Mink Therapeutics, Inc. | T cell receptors that bind to NY-ESO-1 and methods of use thereof |
| CN107474135B (zh) * | 2017-02-17 | 2020-08-18 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用 |
| EP3589652B1 (en) | 2017-03-04 | 2024-12-25 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| WO2018226580A2 (en) | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
| CA3073055A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
| EP3679070A1 (en) | 2017-09-07 | 2020-07-15 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| EP3710477A1 (en) | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Single domain antibodies that bind to cd137 |
| CN108218988B (zh) * | 2017-11-29 | 2019-10-11 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| AR114127A1 (es) * | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| EP3768713A2 (en) | 2018-03-22 | 2021-01-27 | Keires AG | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
| EP3784688A2 (en) | 2018-04-26 | 2021-03-03 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| CN120714025A (zh) | 2018-06-20 | 2025-09-30 | 因赛特公司 | 抗pd-1抗体及其用途 |
| CN113574386A (zh) | 2019-01-03 | 2021-10-29 | 国家医疗保健研究所 | 用于增强癌症患者的cd8+t细胞依赖性免疫应答的方法和药物组合物 |
| CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| EP4002993A4 (en) | 2019-07-30 | 2024-01-10 | Pairwise Plants Services, Inc. | MORPHOGENIC REGULATORS AND METHODS OF USE |
| US11629190B2 (en) | 2019-08-15 | 2023-04-18 | Oregon State University | Canine antibody therapeutic for treating cancer |
| KR102231974B1 (ko) * | 2019-08-23 | 2021-03-25 | 한국과학기술원 | 사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도 |
| US11680098B2 (en) | 2019-08-30 | 2023-06-20 | Agenus Inc. | Antibodies that specifically bind human CD96 |
| CN115279898A (zh) | 2019-10-23 | 2022-11-01 | 成对植物服务股份有限公司 | 用于植物中rna模板化编辑的组合物和方法 |
| CN114867852A (zh) | 2019-10-30 | 2022-08-05 | 成对植物服务股份有限公司 | V型crispr-cas碱基编辑器及其使用方法 |
| KR20220110748A (ko) | 2019-11-05 | 2022-08-09 | 페어와이즈 플랜츠 서비시즈, 인크. | 대립유전자의 rna-코딩된 dna-대체를 위한 조성물 및 방법 |
| JP2023502712A (ja) | 2019-11-21 | 2023-01-25 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法 |
| WO2021113788A1 (en) | 2019-12-06 | 2021-06-10 | Pairwise Plants Services, Inc. | Recruitment methods and compounds, compositions and systems for recruitment |
| EP4097229A1 (en) | 2020-01-30 | 2022-12-07 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| UY39058A (es) | 2020-01-31 | 2021-08-31 | Pairwise Plants Services Inc | Suppresión de la respuesta de evasión a la sombra en plantas |
| US20230063560A1 (en) | 2020-02-04 | 2023-03-02 | Pairwise Plans Services, Inc. | Thornless and/or prickleless rubus plants |
| MX2022010215A (es) | 2020-02-21 | 2022-10-07 | Pairwise Plants Services Inc | Mejora de la resistencia al nematodo del quiste de la soja mediante edicion genetica. |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US11999946B2 (en) | 2020-03-26 | 2024-06-04 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| US11882808B2 (en) | 2020-03-27 | 2024-01-30 | Pairwise Plants Services, Inc. | Methods for improving resistance to soybean rust |
| WO2021207148A1 (en) | 2020-04-06 | 2021-10-14 | Pairwise Plants Services, Inc. | Methods and compositions for increasing resistance to ear rot and stem rot disease in maize |
| WO2021211926A1 (en) | 2020-04-16 | 2021-10-21 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| MX2022013840A (es) * | 2020-05-04 | 2023-02-09 | Inhibrx Inc | Polipéptidos de unión a pd-1 canina y usos de los mismos. |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| LT4157876T (lt) | 2020-05-26 | 2024-10-25 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antikūnai |
| WO2021247477A1 (en) | 2020-06-02 | 2021-12-09 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| CA3186972A1 (en) | 2020-06-17 | 2021-12-23 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| AU2021300169A1 (en) | 2020-06-30 | 2023-02-02 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| KR20230058090A (ko) | 2020-08-28 | 2023-05-02 | 페어와이즈 플랜츠 서비시즈, 인크. | 조작된 crispr-cas 단백질 및 그의 사용 방법 |
| AU2021374974A1 (en) | 2020-11-06 | 2023-05-25 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| CA3210785A1 (en) | 2021-02-11 | 2022-08-18 | Pairwise Plants Services, Inc. | Methods and compositions for modifying cytokinin oxidase levels in plants |
| EP4298118A1 (en) | 2021-02-25 | 2024-01-03 | Pairwise Plants Services, Inc. | Methods and compositions for modifying root architecture in plants |
| CN113189078B (zh) * | 2021-03-04 | 2024-04-16 | 吉林大学 | 一种靶向药物的高通量筛选方法 |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US20220403475A1 (en) | 2021-06-14 | 2022-12-22 | Pairwise Plants Services, Inc. | Reporter constructs, compositions comprising the same, and methods of use thereof |
| US20220411813A1 (en) | 2021-06-17 | 2022-12-29 | Pairwise Plants Services, Inc. | Modification of growth regulating factor family transcription factors in soybean |
| UY39827A (es) | 2021-06-24 | 2023-01-31 | Pairwise Plants Services Inc | Modificación de genes de ubiquitina ligasa e3 hect para mejorar los rasgos de rendimiento |
| CA3224982A1 (en) | 2021-07-01 | 2023-01-05 | Pairwise Plants Services, Inc. | Methods and compositions for enhancing root system development |
| CN113702351B (zh) * | 2021-07-14 | 2024-08-20 | 吉林大学 | 一种对天然药物产物进行筛选和垂钓的方法 |
| EP4384626A1 (en) | 2021-08-12 | 2024-06-19 | Pairwise Plants Services, Inc. | Modification of brassinosteroid receptor genes to improve yield traits |
| UY39902A (es) | 2021-08-17 | 2023-03-31 | Pairwise Plants Services Inc | Métodos y composiciones para modificar genes de histidina quinasa receptores de citoquinina en plant |
| US12359215B2 (en) | 2021-08-30 | 2025-07-15 | Pairwise Plants Services, Inc. | Modification of ubiquitin binding peptidase genes in plants for yield trait improvement |
| AR126938A1 (es) | 2021-09-02 | 2023-11-29 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar la arquitectura de las plantas y los rasgos de rendimiento |
| US20230266293A1 (en) | 2021-09-21 | 2023-08-24 | Pairwise Plants Services, Inc. | Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same |
| CA3232804A1 (en) | 2021-09-21 | 2023-03-30 | Pairwise Plants Services, Inc. | Methods and compositions for reducing pod shatter in canola |
| MX2024004057A (es) | 2021-10-04 | 2024-04-25 | Pairwise Plants Services Inc | Metodos para mejorar la fertilidad de la flor y el rendimiento de semillas. |
| EP4413022A2 (en) | 2021-10-07 | 2024-08-14 | Pairwise Plants Services, Inc. | Methods for improving floret fertility and seed yield |
| AR127904A1 (es) | 2021-12-09 | 2024-03-06 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de floretes y el rendimiento de semillas |
| WO2023114750A1 (en) | 2021-12-13 | 2023-06-22 | Pairwise Plants Services, Inc. | Model editing systems and methods relating to the same |
| WO2023133440A1 (en) | 2022-01-06 | 2023-07-13 | Pairwise Plants Services, Inc. | Methods and compositions for trichome removal |
| AU2023212994A1 (en) | 2022-01-28 | 2024-08-08 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
| AR128372A1 (es) | 2022-01-31 | 2024-04-24 | Pairwise Plants Services Inc | Supresión de la respuesta de evitación de la sombra en las plantas |
| CA3253290A1 (en) | 2022-02-28 | 2023-08-31 | Pairwise Plants Services, Inc. | MODIFIED CRISPR-CAS EFFECTOR PROTEINS AND THEIR METHODS OF USE |
| CN119072487A (zh) | 2022-03-02 | 2024-12-03 | 成对植物服务股份有限公司 | 用于改善产量性状的油菜素类固醇受体基因的修饰 |
| CN115015536A (zh) * | 2022-03-30 | 2022-09-06 | 邹灵龙 | 一种即时检测pd-1抗体药浓度的试纸条和试剂盒 |
| WO2023192838A1 (en) | 2022-03-31 | 2023-10-05 | Pairwise Plants Services, Inc. | Early flowering rosaceae plants with improved characteristics |
| CA3247405A1 (en) | 2022-04-07 | 2023-10-12 | Pairwise Plants Services, Inc. | METHODS AND COMPOSITIONS FOR IMPROVING RESISTANCE TO FUSARIA BROAD OF THE SPINE |
| WO2023205714A1 (en) | 2022-04-21 | 2023-10-26 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield traits |
| WO2023215704A1 (en) | 2022-05-02 | 2023-11-09 | Pairwise Plants Services, Inc. | Methods and compositions for enhancing yield and disease resistance |
| WO2023215809A1 (en) | 2022-05-05 | 2023-11-09 | Pairwise Plants Services, Inc. | Methods and compositions for modifying root architecture and/or improving plant yield traits |
| UY40326A (es) | 2022-06-27 | 2023-12-29 | Pairwise Plants Services Inc | Métodos y composiciones para modificar el escape a la sombra en plantas |
| CN119365481A (zh) | 2022-06-29 | 2025-01-24 | 成对植物服务股份有限公司 | 用于控制分生组织大小以进行作物改良的方法和组合物 |
| CN119487055A (zh) | 2022-06-29 | 2025-02-18 | 成对植物服务股份有限公司 | 用于控制分生组织大小以进行作物改良的方法和组合物 |
| WO2024030984A1 (en) | 2022-08-04 | 2024-02-08 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield traits |
| CN119654065A (zh) | 2022-08-11 | 2025-03-18 | 成对植物服务股份有限公司 | 用于控制分生组织大小以进行作物改良的方法和组合物 |
| CA3266121A1 (en) | 2022-09-08 | 2024-03-14 | Pairwise Plants Services, Inc. | METHODS AND COMPOSITIONS FOR IMPROVING YIELD CHARACTERISTICS IN PLANTS |
| AU2023395894A1 (en) | 2022-12-16 | 2025-06-05 | Pairwise Plants Services, Inc. | Fusion proteins comprising an intein polypeptide and methods of use thereof |
| WO2024137911A1 (en) | 2022-12-21 | 2024-06-27 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| EP4665747A1 (en) | 2023-02-16 | 2025-12-24 | Pairwise Plants Services, Inc. | Methods and compositions for modifying shade avoidance in plants |
| WO2024182746A1 (en) | 2023-03-01 | 2024-09-06 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| AR132019A1 (es) | 2023-03-02 | 2025-05-21 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la evitación de la sombra en plantas |
| AR132071A1 (es) | 2023-03-09 | 2025-05-21 | Pairwise Plants Services Inc | Modificación de genes de la vía de señalización de brasinoesteroide para mejorar rasgos de rendimiento en plantas |
| AU2024248777A1 (en) | 2023-03-30 | 2025-10-02 | Pairwise Plants Services, Inc. | Methods and compositions for reducing thorns or prickles in plants |
| WO2024216028A1 (en) | 2023-04-12 | 2024-10-17 | Agenus Inc. | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |
| US20240400687A1 (en) | 2023-05-10 | 2024-12-05 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| UY40746A (es) | 2023-05-18 | 2024-12-13 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar las características de rendimiento de las plantas |
| AR133164A1 (es) | 2023-07-18 | 2025-09-03 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la arquitectura radicular en plantas |
| AR133310A1 (es) | 2023-07-27 | 2025-09-17 | Pairwise Plants Services Inc | Métodos y composiciones para modificar rasgos de rendimiento de las plantas |
| WO2025064734A1 (en) | 2023-09-21 | 2025-03-27 | Pairwise Plants Services, Inc. | Early flowering black raspberry plants with improved characteristics |
| WO2025072430A1 (en) | 2023-09-26 | 2025-04-03 | Pairwise Plants Services, Inc. | Crispr-cas fusion proteins with adenine base editor functionality, compositions comprising the same, and methods of use thereof |
| WO2025080537A1 (en) | 2023-10-09 | 2025-04-17 | Pairwise Plants Services, Inc. | Circular permutants of cas12a |
| US20250122522A1 (en) | 2023-10-11 | 2025-04-17 | Pairwise Plants Services, Inc. | Methods and compositions for improving crop yield traits |
| US20250207154A1 (en) | 2023-12-21 | 2025-06-26 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| WO2025178902A1 (en) | 2024-02-22 | 2025-08-28 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield characteristics in plants |
| WO2025252857A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | Il-15 muteins with ph-dependent binding for il-15ralpha |
| WO2025252855A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta |
| US12428636B1 (en) | 2024-07-08 | 2025-09-30 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3011939B2 (ja) | 1987-03-02 | 2000-02-21 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 組換えミコバクテリア・ワクチン |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| WO1991013157A1 (en) | 1990-02-26 | 1991-09-05 | Commonwealth Scientific And Industrial Research Organisation | Shuttle plasmid for escherichia coli and mycobacteria |
| GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU2185592A (en) | 1991-06-06 | 1993-01-08 | Med Immune, Inc. | Induction of ctl responses to foreign antigens expressed in mycobacteria |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| JP3454275B2 (ja) | 1992-06-05 | 2003-10-06 | 佑 本庶 | プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ |
| AU7203194A (en) | 1993-06-04 | 1995-01-03 | New York University | Bispecific human monoclonal antibodies specific for human immunodeficiency virus |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Ｐｄ−１に対し特異性を有する物質 |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| JP2007524348A (ja) | 2003-01-07 | 2007-08-30 | ダイアックス、コープ | クニッツドメインライブラリー |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| EP2439273B1 (en) * | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| TW201007669A (en) | 2008-08-01 | 2010-02-16 | Integrated Solutions Technology Inc | A display driving device and the driving method thereof |
| WO2010029435A1 (en) * | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| WO2010029434A1 (en) * | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| CA2790134A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
| CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| CN107090029B (zh) | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| AU2012236479B2 (en) | 2011-03-31 | 2016-10-20 | Merck Sharp & Dohme Llc | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| US9090994B2 (en) | 2011-06-08 | 2015-07-28 | Nanjingjinsirui Science & Technology Biology Corp. | Antibody humanization by framework assembly |
| MY193562A (en) | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| AU2013201121A1 (en) | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| JP2015509592A (ja) * | 2012-02-23 | 2015-03-30 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 免疫調節治療剤を用いた処置に対する反応性の予測及びこのような処置の間のアブスコパル効果をモニターする方法 |
| WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US20150290316A1 (en) * | 2012-10-02 | 2015-10-15 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| PT3702373T (pt) * | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PL3177644T3 (pl) * | 2014-08-05 | 2021-06-14 | MabQuest SA | Immunologiczne reagenty wiążące do PD-1 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| WO2017125815A2 (en) * | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
-
2015
- 2015-08-05 PL PL15750136T patent/PL3177644T3/pl unknown
- 2015-08-05 AU AU2015298356A patent/AU2015298356B2/en active Active
- 2015-08-05 CA CA2957258A patent/CA2957258C/en active Active
- 2015-08-05 PT PT157501362T patent/PT3177644T/pt unknown
- 2015-08-05 ES ES15750136T patent/ES2847311T3/es active Active
- 2015-08-05 KR KR1020177004575A patent/KR102357893B1/ko active Active
- 2015-08-05 US US15/329,760 patent/US9982053B2/en active Active
- 2015-08-05 EP EP15750136.2A patent/EP3177644B1/en active Active
- 2015-08-05 SG SG11201700672YA patent/SG11201700672YA/en unknown
- 2015-08-05 DK DK15750136.2T patent/DK3177644T3/da active
- 2015-08-05 CN CN201580042199.7A patent/CN107074947B/zh active Active
- 2015-08-05 JP JP2017526774A patent/JP6629321B2/ja active Active
- 2015-08-05 WO PCT/IB2015/055943 patent/WO2016020856A2/en not_active Ceased
-
2018
- 2018-05-17 US US15/981,977 patent/US11130807B2/en active Active
-
2021
- 2021-09-27 US US17/485,752 patent/US20220169733A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016020856A3 (en) | 2016-03-31 |
| KR20170069996A (ko) | 2017-06-21 |
| KR102357893B1 (ko) | 2022-02-04 |
| EP3177644B1 (en) | 2020-10-07 |
| US11130807B2 (en) | 2021-09-28 |
| US20220169733A1 (en) | 2022-06-02 |
| JP2017531028A (ja) | 2017-10-19 |
| CA2957258A1 (en) | 2016-02-11 |
| CA2957258C (en) | 2023-11-07 |
| AU2015298356B2 (en) | 2020-11-19 |
| US20190106493A1 (en) | 2019-04-11 |
| US9982053B2 (en) | 2018-05-29 |
| CN107074947A (zh) | 2017-08-18 |
| CN107074947B (zh) | 2021-04-09 |
| US20170226210A1 (en) | 2017-08-10 |
| AU2015298356A1 (en) | 2017-02-16 |
| EP3177644A2 (en) | 2017-06-14 |
| PT3177644T (pt) | 2021-01-13 |
| ES2847311T3 (es) | 2021-08-02 |
| WO2016020856A2 (en) | 2016-02-11 |
| DK3177644T3 (da) | 2021-01-11 |
| SG11201700672YA (en) | 2017-02-27 |
| JP6629321B2 (ja) | 2020-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285287B1 (en) | Antibodies to tigit | |
| SG11201700672YA (en) | Immunological reagents binding to pd-1 | |
| IL267798B (en) | Human antibodies to pd-1 | |
| IL261188A (en) | Antibodies against tigit | |
| IL256844A (en) | pd-1 antibodies | |
| IL256499A (en) | Antibodies to CD40 | |
| IL249187A0 (en) | Antibodies to il-15 | |
| PL3146010T3 (pl) | Środki wiążące | |
| ZA201604640B (en) | Novel anti-netrin-1 antibody | |
| SI3628731T1 (sl) | Novo protitelo proti presepsinu | |
| ZA201800781B (en) | Pd-1 antibodies | |
| HK1244290A1 (en) | Antibodies to tigit | |
| GB201507228D0 (en) | Antibodies to IL-24 | |
| AU2014903840A0 (en) | Immunological reagent | |
| AU2014903652A0 (en) | Immunological reagent | |
| GB201409276D0 (en) | Improvements to vehicle transmissions | |
| AU2014902976A0 (en) | App to app payment | |
| GB201417640D0 (en) | Binding Assay Analysis |